Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...
Phantasy Star Online 2: New Genesis is the ultimate PSO2 experience in which the time-tested elements are kept intact, while the game design, gameplay and graphics engine will be completely redesigned ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results